Utah Medical Products (NASDAQ: UTMD) stock: the official figures
Utah Medical Products (UTAH MEDICAL PRODUCTS, INC.) is listed on Nasdaq under the ticker UTMD and belongs to the health care sector. In fiscal 2025 it reported revenue of $38.5m and a net profit of $11.3m, according to the annual accounts it filed with the regulator.
Identifiers for Utah Medical Products: SEC CIK 706698.
Fiscal 2025 figures
| Item | 2025 | 2024 | Change |
|---|---|---|---|
| Revenue | $38.5m | $40.9m | −5.8% |
| Operating profit | $11.4m | $13.6m | −16.1% |
| Net profit | $11.3m | $13.9m | −18.7% |
| Earnings per share | $3.48 | $3.96 | −12.1% |
| Operating margin | 29.6% | 33.2% | −3.6 pts |
| Net margin | 29.3% | 33.9% | −4.6 pts |
| Total assets | $122.5m | $122.5m | 0.0% |
| Equity | $119.3m | $117.4m | +1.6% |
| Cash | $85.8m | $83.0m | +3.4% |
| Operating cash flow | $14.7m | $14.8m | −0.9% |
Margins are calculated from the filed figures: operating profit and net profit over revenue.
10 fiscal years
| Fiscal year | Revenue | Operating profit | Net profit | Earnings per share | Document |
|---|---|---|---|---|---|
| 2025 | $38.5m | $11.4m | $11.3m | $3.48 | Annual report |
| 2024 | $40.9m | $13.6m | $13.9m | $3.96 | Annual report |
| 2023 | $50.2m | $16.8m | $16.6m | $4.58 | Annual report |
| 2022 | $52.3m | $19.8m | $16.5m | $4.53 | Annual report |
| 2021 | $49.1m | $18.9m | $14.8m | $4.05 | Annual report |
| 2020 | $42.2m | $13.7m | $10.8m | $2.95 | Annual report |
| 2019 | $46.9m | $17.6m | $14.7m | $3.96 | Annual report |
| 2018 | $42.0m | $18.7m | $18.6m | $4.97 | Annual report |
| 2017 | $41.4m | $19.0m | $8.5m | $2.29 | Annual report |
| 2016 | $39.3m | $16.2m | $12.1m | $3.23 | Annual report |
The full income statement, balance sheet and cash flow statement are in the annual accounts of Utah Medical Products. Year by year: dividends paid. Purchases and sales by its executives and directors are in insider transactions.
Dividends
In fiscal 2025, Utah Medical Products paid $4.0m in dividends, 35.3% of its net profit, according to its cash flow statement.
| Fiscal year | Dividends paid | Share of net profit |
|---|---|---|
| 2025 | $4.0m | 35.3% |
| 2024 | $4.3m | 30.7% |
| 2023 | $4.3m | 25.7% |
| 2022 | $3.2m | 19.2% |
| 2021 | $11.5m | 77.5% |
| 2020 | $4.1m | 38.1% |
| 2019 | $4.1m | 27.9% |
| 2018 | $4.0m | 21.7% |
| 2017 | $3.0m | 34.7% |
| 2016 | $3.9m | 32.3% |
Cash paid out as dividends during the fiscal year, including dividends to minority shareholders of subsidiaries when the company does not report them separately. It is not the dividend per share.
Frequently asked questions about Utah Medical Products
- How much did Utah Medical Products earn in fiscal 2025?
- Utah Medical Products reported a net profit of $11.3m for fiscal 2025, on revenue of $38.5m. The year before it reported a net profit of $13.9m.
- Does Utah Medical Products pay a dividend?
- In fiscal 2025, Utah Medical Products paid $4.0m in dividends, 35.3% of its net profit, according to its cash flow statement.
- What are the earnings per share of Utah Medical Products?
- They were $3.48 in fiscal 2025, compared with $3.96 the year before.
- Where is Utah Medical Products listed?
- Utah Medical Products is listed on Nasdaq under the ticker UTMD and belongs to the health care sector.
- Where do the figures for Utah Medical Products come from?
- From the annual report (Form 10-K) that Utah Medical Products files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
The annual accounts come from the annual report (Form 10-K) that Utah Medical Products files with the SEC, the US securities regulator. Each fiscal year in the table links to its filing. Celsmar reads the tagged figures from the document and does not adjust them: if an item is not in the filing, it is not shown. More detail in data sources and, if you spot an error, in corrections. What Celsmar is and what it costs, in its fact sheet.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.